News
Public · Published
Mirum Pharmaceuticals Q3 net product sales surge, outlook raised
Mirum Pharmaceuticals reported third-quarter net product sales of $185.72 mln and a net loss of $40.77 mln. It raised its full-year 2026 net product sales outlook to $715 mln–$720 mln. LIVMARLI sales grew 45% year over year, and Bile Acid Medicines sales rose 28%.
Published:
Updated:
What happened
Mirum Pharmaceuticals reported third-quarter net product sales of $185.72 mln and a net loss of $40.77 mln. It raised its full-year 2026 net product sales outlook to $715 mln–$720 mln. LIVMARLI sales grew 45% year over year, and Bile Acid Medicines sales rose 28%.
Confirmed
Global impact / market context
Growing product sales and a higher outlook point to stronger demand that could expand future revenue. But the quarterly loss alongside operating expenses of $245.47 mln shows costs remain substantial, so sales growth has not yet translated into a profit for investors to assess.
Analyst inference
The article reports a $153 median 12-month analyst price target, about 78.4% above Mirum’s November 2 closing price of $85.74, and an average buy rating. These are analyst views, not guarantees of future share performance.
Confirmed
What to watch
- Compare future sales reports with the raised full-year outlook, and assess whether growth across Mirum’s medicines continues strongly enough to support the company’s stated expectations. Analyst inference
- Review operating expenses and net losses in subsequent results: if costs keep rising faster than sales, additional product revenue may not improve the company’s financial results. Analyst inference
- The company attributed LIVMARLI growth to expansion into additional rare cholestatic liver diseases; it said Bile Acid Medicines sales rose with increased demand for CHOLBAM and CTEXLI. Confirmed
Evidence
- Original source link unavailable